Annual Report for FY 2024-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Concord Drugs Limited, a Telangana-based pharmaceutical company listed on BSE, submitted its Annual Report for FY 2024-25 along with the notice for its 30th Annual General Meeting. The AGM is scheduled for September 30, 2025, at 9:30 AM via video conferencing, with the record date set as September 23, 2025. Shareholders will vote on ordinary items like adopting financial statements and reappointing a director by rotation, plus several special items. Key resolutions include approving related party transactions up to Rs. 15 crore each with four promoter-linked entities (Proton Remedies, Cortex Laboratories, Seelam Laboratories, and Continental Pellets Pharma). Other items cover appointing PSK & Associates as secretarial auditors for five years, adding a new independent director, and reappointing the CMD and two whole-time directors with fixed monthly remuneration. The document also includes standard AGM procedure details such as remote e-voting via CDSL.
Investors should note the substantial related party transaction limits (up to Rs. 15 crore each with promoter-related companies) that are up for shareholder approval, as these involve entities connected to the company's directors. The reappointment of the existing management team with defined remuneration and the addition of a new independent director indicate continuity at the leadership level. There is no major negative signal in this filing—it is primarily a routine AGM and annual report submission.